NASDAQ:GNFTGENFIT S A/ADR Stock Price, Forecast & News

GENFIT S A/ADR's stock was trading at $14.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GNFT stock has decreased by 61.8% and is now trading at $5.44. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GENFIT S A/ADR in the last year. There are currently 3 sell ratings, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for GENFIT S A/ADR.

GENFIT S A/ADR is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for GENFIT S A/ADR.

9 brokerages have issued 1-year price targets for GENFIT S A/ADR's stock. Their forecasts range from $7.00 to $174.00. On average, they anticipate GENFIT S A/ADR's stock price to reach $45.20 in the next year. This suggests a possible upside of 730.9% from the stock's current price. View analysts' price targets for GENFIT S A/ADR.

News stories about GNFT stock have been trending negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GENFIT S A/ADR earned a daily sentiment score of -2.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next several days. View the latest news about GENFIT S A/ADR.

Some companies that are related to GENFIT S A/ADR include Replimune Group (REPL), Cellectis (CLLS), Krystal Biotech (KRYS), Vericel (VCEL), Agenus (AGEN), Osiris Therapeutics (OSIR), Aerie Pharmaceuticals (AERI), AVITA MED LTD/S (RCEL), Avrobio (AVRO), Proteon Therapeutics (PRTO), Oyster Point Pharma (OYST), Autolus Therapeutics (AUTL), Aptose Biosciences (APTO), Orchard Therapeutics (ORTX) and Vaxart (VXRT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GENFIT S A/ADR investors own include Intercept Pharmaceuticals (ICPT), InterDigital Wireless (IDCC), Stag Industrial (STAG), Amarin (AMRN), Gilead Sciences (GILD), Zynerba Pharmaceuticals (ZYNE), Vaxart (VXRT), Agile Therapeutics (AGRX), Aimmune Therapeutics (AIMT) and Advanced Micro Devices (AMD).

(GNFT) raised $132 million in an initial public offering (IPO) on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays served as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

GENFIT S A/ADR trades on the NASDAQ under the ticker symbol "GNFT."

Shares of GNFT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GNFT stock can currently be purchased for approximately $5.44.

GENFIT S A/ADR has a market capitalization of $205.80 million and generates $45.88 million in revenue each year. The company earns $-72,960,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. GENFIT S A/ADR employs 148 workers across the globe.

The official website for GENFIT S A/ADR is www.genfit.com.

GENFIT S A/ADR's mailing address is PARC 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The company can be reached via phone at 33-3-20-16-40-00 or via email at [email protected]